Cargando…

Hsa-miRNA-143-3p Reverses Multidrug Resistance of Triple-Negative Breast Cancer by Inhibiting the Expression of Its Target Protein Cytokine-Induced Apoptosis Inhibitor 1 In Vivo

PURPOSE: Multidrug resistance (MDR) remains a major obstacle in the treatment of triple-negative breast cancer (TNBC) with conventional chemotherapeutic agents. A previous study demonstrated that hsa-miRNA-143-3p plays a vital role in drug resistance of TNBC. Downregulation of hsa-miRNA-143-3p upreg...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Yu Wei, Hao, Wen Jing, Li, Yi Wen, Li, Yi Xin, Zhao, Bo Chen, Lu, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158160/
https://www.ncbi.nlm.nih.gov/pubmed/30275853
http://dx.doi.org/10.4048/jbc.2018.21.e40
_version_ 1783358372377001984
author Deng, Yu Wei
Hao, Wen Jing
Li, Yi Wen
Li, Yi Xin
Zhao, Bo Chen
Lu, Dan
author_facet Deng, Yu Wei
Hao, Wen Jing
Li, Yi Wen
Li, Yi Xin
Zhao, Bo Chen
Lu, Dan
author_sort Deng, Yu Wei
collection PubMed
description PURPOSE: Multidrug resistance (MDR) remains a major obstacle in the treatment of triple-negative breast cancer (TNBC) with conventional chemotherapeutic agents. A previous study demonstrated that hsa-miRNA-143-3p plays a vital role in drug resistance of TNBC. Downregulation of hsa-miRNA-143-3p upregulated the expression of its target protein cytokine-induced apoptosis inhibitor 1 (CIAPIN1) in order to activate MDR, while upregulation of hsa-miRNA-143-3p effectively enhances the sensitivity of drug-resistant TNBC cells to chemotherapeutics. The present study aimed to further verify these findings in vivo. METHODS: We established a hypodermic tumor nude mice model using paclitaxel-resistant TNBC cells. We expressed ectopic hsa-miRNA-143-3p under the control of a breast cancer-specific human mammaglobin promoter that guided the efficient expression of exogenous hsa-miRNA-143-3p only in breast cancer cells. Thereafter, we overexpressed hsa-miRNA-143-3p in xenografts using a recombinant virus system and quantified the expression of hsa-miRNA-143-3p, CIAPIN1 protein, and proteins encoded by related functional genes by western blot. RESULTS: We successfully completed the prospective exploration of the intravenous virus injection pattern from extensive expression to targeted expression. The overexpression of hsa-miRNA-143-3p significantly alleviated chemoresistance of TNBC by inhibiting viability. In addition, we observed that the expression of CIAPIN1 as a hsa-miRNA-143-3p target protein was remarkably decreased. CONCLUSION: We partly illustrated the mechanism underlying the hsa-miRNA-143-3p/CIAPIN1 drug resistance pathway. HsamiRNA-143-3p as a tumor suppressive microRNA may be a novel target to effectively reverse MDR of TNBC in vivo.
format Online
Article
Text
id pubmed-6158160
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Korean Breast Cancer Society
record_format MEDLINE/PubMed
spelling pubmed-61581602018-10-01 Hsa-miRNA-143-3p Reverses Multidrug Resistance of Triple-Negative Breast Cancer by Inhibiting the Expression of Its Target Protein Cytokine-Induced Apoptosis Inhibitor 1 In Vivo Deng, Yu Wei Hao, Wen Jing Li, Yi Wen Li, Yi Xin Zhao, Bo Chen Lu, Dan J Breast Cancer Original Article PURPOSE: Multidrug resistance (MDR) remains a major obstacle in the treatment of triple-negative breast cancer (TNBC) with conventional chemotherapeutic agents. A previous study demonstrated that hsa-miRNA-143-3p plays a vital role in drug resistance of TNBC. Downregulation of hsa-miRNA-143-3p upregulated the expression of its target protein cytokine-induced apoptosis inhibitor 1 (CIAPIN1) in order to activate MDR, while upregulation of hsa-miRNA-143-3p effectively enhances the sensitivity of drug-resistant TNBC cells to chemotherapeutics. The present study aimed to further verify these findings in vivo. METHODS: We established a hypodermic tumor nude mice model using paclitaxel-resistant TNBC cells. We expressed ectopic hsa-miRNA-143-3p under the control of a breast cancer-specific human mammaglobin promoter that guided the efficient expression of exogenous hsa-miRNA-143-3p only in breast cancer cells. Thereafter, we overexpressed hsa-miRNA-143-3p in xenografts using a recombinant virus system and quantified the expression of hsa-miRNA-143-3p, CIAPIN1 protein, and proteins encoded by related functional genes by western blot. RESULTS: We successfully completed the prospective exploration of the intravenous virus injection pattern from extensive expression to targeted expression. The overexpression of hsa-miRNA-143-3p significantly alleviated chemoresistance of TNBC by inhibiting viability. In addition, we observed that the expression of CIAPIN1 as a hsa-miRNA-143-3p target protein was remarkably decreased. CONCLUSION: We partly illustrated the mechanism underlying the hsa-miRNA-143-3p/CIAPIN1 drug resistance pathway. HsamiRNA-143-3p as a tumor suppressive microRNA may be a novel target to effectively reverse MDR of TNBC in vivo. Korean Breast Cancer Society 2018-09 2018-09-12 /pmc/articles/PMC6158160/ /pubmed/30275853 http://dx.doi.org/10.4048/jbc.2018.21.e40 Text en © 2018 Korean Breast Cancer Society http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Deng, Yu Wei
Hao, Wen Jing
Li, Yi Wen
Li, Yi Xin
Zhao, Bo Chen
Lu, Dan
Hsa-miRNA-143-3p Reverses Multidrug Resistance of Triple-Negative Breast Cancer by Inhibiting the Expression of Its Target Protein Cytokine-Induced Apoptosis Inhibitor 1 In Vivo
title Hsa-miRNA-143-3p Reverses Multidrug Resistance of Triple-Negative Breast Cancer by Inhibiting the Expression of Its Target Protein Cytokine-Induced Apoptosis Inhibitor 1 In Vivo
title_full Hsa-miRNA-143-3p Reverses Multidrug Resistance of Triple-Negative Breast Cancer by Inhibiting the Expression of Its Target Protein Cytokine-Induced Apoptosis Inhibitor 1 In Vivo
title_fullStr Hsa-miRNA-143-3p Reverses Multidrug Resistance of Triple-Negative Breast Cancer by Inhibiting the Expression of Its Target Protein Cytokine-Induced Apoptosis Inhibitor 1 In Vivo
title_full_unstemmed Hsa-miRNA-143-3p Reverses Multidrug Resistance of Triple-Negative Breast Cancer by Inhibiting the Expression of Its Target Protein Cytokine-Induced Apoptosis Inhibitor 1 In Vivo
title_short Hsa-miRNA-143-3p Reverses Multidrug Resistance of Triple-Negative Breast Cancer by Inhibiting the Expression of Its Target Protein Cytokine-Induced Apoptosis Inhibitor 1 In Vivo
title_sort hsa-mirna-143-3p reverses multidrug resistance of triple-negative breast cancer by inhibiting the expression of its target protein cytokine-induced apoptosis inhibitor 1 in vivo
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158160/
https://www.ncbi.nlm.nih.gov/pubmed/30275853
http://dx.doi.org/10.4048/jbc.2018.21.e40
work_keys_str_mv AT dengyuwei hsamirna1433preversesmultidrugresistanceoftriplenegativebreastcancerbyinhibitingtheexpressionofitstargetproteincytokineinducedapoptosisinhibitor1invivo
AT haowenjing hsamirna1433preversesmultidrugresistanceoftriplenegativebreastcancerbyinhibitingtheexpressionofitstargetproteincytokineinducedapoptosisinhibitor1invivo
AT liyiwen hsamirna1433preversesmultidrugresistanceoftriplenegativebreastcancerbyinhibitingtheexpressionofitstargetproteincytokineinducedapoptosisinhibitor1invivo
AT liyixin hsamirna1433preversesmultidrugresistanceoftriplenegativebreastcancerbyinhibitingtheexpressionofitstargetproteincytokineinducedapoptosisinhibitor1invivo
AT zhaobochen hsamirna1433preversesmultidrugresistanceoftriplenegativebreastcancerbyinhibitingtheexpressionofitstargetproteincytokineinducedapoptosisinhibitor1invivo
AT ludan hsamirna1433preversesmultidrugresistanceoftriplenegativebreastcancerbyinhibitingtheexpressionofitstargetproteincytokineinducedapoptosisinhibitor1invivo